A5067939562- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Venous Thromboembolism Diagnosis and Management
- Kruppel-like factors research
- Chronic Myeloid Leukemia Treatments
- Hemoglobinopathies and Related Disorders
- Cytokine Signaling Pathways and Interactions
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Erythropoietin and Anemia Treatment
- Platelet Disorders and Treatments
- Hepatitis C virus research
- Acute Ischemic Stroke Management
- Hematological disorders and diagnostics
- Hematopoietic Stem Cell Transplantation
- Advanced Neuroimaging Techniques and Applications
- Cardiac pacing and defibrillation studies
- Genetic factors in colorectal cancer
- Fungal Infections and Studies
- Frailty in Older Adults
- Blood disorders and treatments
- Mast cells and histamine
Washington University in St. Louis
2016-2025
Saskatoon Medical Imaging
2024
University of Saskatchewan
2023
Merck & Co., Inc., Rahway, NJ, USA (United States)
2013
University of Oklahoma Health Sciences Center
1997
Background: Combined hepatocellular-cholangiocarcinoma tumors (cHCC-CCA) are a heterogeneous group of rare malignancies that have no established optimal treatment. Patients and Methods: We identified patients with cHCC-CCA treated at tertiary center retrospectively examined their histology, interventions, outcomes. calculated disease control rate (DCR), progression, overall survival, progression-free survival (PFS) between treatment subgroups. Results: A total 123 were evaluable....
Abstract Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved for of anemia chronic kidney disease UK, EU, China, Japan, South Korea, Chile. MATTERHORN phase 3, randomized, double‐blind, placebo‐controlled study to assess efficacy safety roxadustat lower risk‐MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, low packed RBC transfusion burden....
Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30–40% patients develop resistance to imatinib therapy. Although most is caused by mutations in BCR-ABL domain, 50–85% these absence new mutations. In cases, targeting other pathways may be needed regain clinical response. Using label-free Raman spectromicroscopy, we evaluated a number cell lines discovered an aberrant...
Factor (F)XI is a zymogen that contributes to thrombin generation through activation of FIX. Patients with complete absence FXI are prone developing alloantibody inhibitors after replacement therapy. Acquired autoantibodies less common, and data regarding their mechanisms action lacking. We describe 2 patients severe acquired deficiency identify the domains which bind. prekallikrein (PK) homologs similar structures. prepared recombinant human PK, as well chimeric molecules in individual...
Human natural killer (NK) cells and T lymphocytes can bind to inhibit the growth of yeast-like organism Cryptococcus neoformans. Binding target NK or also has potential modulate cytokine production by effector cells. In this study, we assessed ability C. neoformans cell production, in some cases T-cell granulocyte-macrophage colony-stimulating factor (GM-CSF) tumor necrosis alpha (TNF-alpha). We found that freshly isolated human from most individuals make GM-CSF TNF-alpha constitutively when...
Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors with features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). These associated a poor overall prognosis treatment is not well defined. Research over the past 20 years has identified aberrations in several molecular pathways, including epidermal growth factor receptor (EGFR) vascular endothelial (VEGF) biliary tract cancers. discoveries led to evaluation targeted therapies,...
Janus kinase 2 (JAK2) inhibitors such as ruxolitinib have become standard-of-care therapy for patients with myeloproliferative neoplasms (MPNs); however, activation of alternate oncogenic pathways including nuclear factor kappa-light-chain-enhancer activated B cells (NFκB) has limited durable response single-agent therapy. With the rationale targeting both pathways, we conducted a phase I dose escalation trial pevonedistat in combination treatment myelofibrosis (NCT03386214). The primary...